Evidity Health Capital

Evidity invests only after a product has achieved regulatory clearance and is commercially available — most healthcare venture firms take earlier-stage, pre-revenue or pre-regulatory risk. This evidence-based mandate means portfolio companies like Augmedics and GT Medical Technologies already had FDA-cleared devices on the market when Evidity committed capital. The firm acts as a growth-equity provider for proven technologies that need scale funding, not seed or Series A discovery capital.

Evidity targets three sectors exclusively: medical devices, in vitro diagnostics, and digital health. It explicitly avoids preclinical biotech, drug discovery, and early-stage therapeutics. The portfolio page confirms every active company operates in one of those three lanes — augmented-reality surgery, implantable radiation therapy, voice-based diagnostics, and precision oncology testing.